Poniard Pharmaceuticals Inc
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplat… Read more
Market Cap & Net Worth: Poniard Pharmaceuticals Inc (PARD)
Poniard Pharmaceuticals Inc (PINK:PARD) has a market capitalization of $149.92 ($149.92) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #51560 globally and #16226 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Poniard Pharmaceuticals Inc's stock price $0.00 by its total outstanding shares 1499159 (1.50 Million).
Poniard Pharmaceuticals Inc Market Cap History: 2015 to 2025
Poniard Pharmaceuticals Inc's market capitalization history from 2015 to 2025. Data shows change from $209.88K to $149.92 (-50.66% CAGR).
Poniard Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Poniard Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PARD by Market Capitalization
Companies near Poniard Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Poniard Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Poniard Pharmaceuticals Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Poniard Pharmaceuticals Inc's market cap moved from $209.88K to $ 149.92, with a yearly change of -50.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $149.92 | 0.00% |
| 2024 | $149.92 | -99.00% |
| 2023 | $14.99K | 0.00% |
| 2022 | $14.99K | 0.00% |
| 2021 | $14.99K | -66.67% |
| 2020 | $44.97K | +63.93% |
| 2019 | $27.43K | -39.00% |
| 2018 | $44.97K | -40.00% |
| 2017 | $74.96K | -37.50% |
| 2016 | $119.93K | -42.86% |
| 2015 | $209.88K | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Poniard Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $149.92 USD |
| MoneyControl | $149.92 USD |
| MarketWatch | $149.92 USD |
| marketcap.company | $149.92 USD |
| Reuters | $149.92 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.